Cover Image
市場調查報告書

全球非小細胞肺癌(NSCLC)治療市場與開發平台分析

Global Non Small Cell Lung Cancer Market & Pipeline Insight

出版商 KuicK Research 商品編碼 322276
出版日期 內容資訊 英文 750 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球非小細胞肺癌(NSCLC)治療市場與開發平台分析 Global Non Small Cell Lung Cancer Market & Pipeline Insight
出版日期: 2015年01月01日 內容資訊: 英文 750 Pages
簡介

肺癌在數十年來都是全球最常見,且罹患率、死亡率最大的癌症。肺臟是位於胸腔的一組海綿組織,和周圍的環境進行氣體交換。這些組織容易受到環境及細胞中所含毒素的侵害,長期暴露在有害氣體下便容易造成癌性增殖(腫瘤)。肺癌可大致區分為二大種類,分別為小細胞肺癌症(SCLC)和非小細胞肺癌(NSCLC)。NSCLC是有抽煙習慣的人最最常見肺癌種類。

本報告提供全球非小細胞肺癌(NSCLC)治療市場相關調查分析,提供您市場概要,治療的機制,市場動態(推動因素,課題,未來預測),開發平台(Phase別,各企業,各國),臨床實驗平台,上市產品等相關的系統性資訊。

第1章 非小細胞肺癌概要

第2章 非小細胞肺癌治療方法的機制

第3章 非小細胞肺癌治療市場概要

  • 市場方案
  • 非小細胞肺癌開發平台概要

第4章 非小細胞肺癌治療的市場動態

  • 推動市場要素
  • 課題

第5章 非小細胞肺癌治療市場未來發展預測

第6章 非小細胞肺癌治療藥開發平台:Phase別,各企業,各國

  • 不明
  • 研究
  • 前臨床
  • 臨床
  • 第一階段
  • 第I/II相
  • 第二階段
  • 第II/III相
  • 認證前
  • 已認證

第7章 上市的非小細胞肺癌治療藥

第8章 開發中斷/中止的非小細胞肺癌治療藥開發平台

  • 無開發報告
  • 中止
  • 中斷

第9章 競爭情形

  • AstraZeneca
  • Biodesix
  • 中外製藥
  • Eli Lily
  • GlaxoSmithKline
  • Merck
  • Novartis AG
  • Pfizer
  • Roche
  • Transgene

圖表

目錄

Lung cancer has become one of the most prevalent cause of cancer related morbidity and mortality in past several decades across the world. Lungs are a pair of spongy tissues present in the thoracic cavity responsible for gaseous exchange from the surrounding environment. These tissues could be easily damaged by the toxins present in environment and cells may show cancerous growth upon longer exposure. The lung cancer is a collective term for cancer development in lungs, it could be divided into two broad categories: Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). It has been observed that NSCLC is the most prevalent type of lung cancer commonly associated with the people practicing the bad habit of cigarette smoking.

Surgery and radiation treatment has been found to have modest effect on NSCL while chemotherapy is largely ineffective due to refractory nature of the cancerous cells. Tumor removal was one of the widely used treatments when effective therapeutics was not available to the patients. Over time, radiation therapy made its place but large number of side effects limited its widespread usage and it was replaced by radiofrequency ablation method which is used to destroy on spot lung tumor cells with the help of high frequency radio waves. Advent of chemotherapeutics medicines helped the patients undergoing surgery or radiation therapy upto limited extent. Targeted therapies came after chemotherapy and they made place in market due to higher safety and efficacy levels.

Targeted therapeutics seems to overtake the NSCLC market due to higher safety and efficacy profiles. Moreover, pharmaceutical companies are promoting them as a replacement for chemotherapeutics which used to dominate in NSCLC therapeutic market. In few cases, combinatorial therapies chemotherapeutics are used with targeted therapeutics but their market share is in decline and this trend is expected to be continued in future. Targeted therapeutics should not be considered as all-in-one treatment as they also have few limitations which are expected to be resolved in near future. The new generation of targeted therapeutics is expected to have refinement at the level of design which will be considered as evolved version of presently available targeted therapeutics.

Advances in monoclonal antibody (mAbs) development technology are expected to evolve further in coming years due to which they may become major NSCLC therapeutic in market. Their potency is expected to increase along with minimum side effects and increase in specificity. The marketing potential of mAbs is expected to increase as they have proven track record and widely accepted by oncologists and patients. The developers of mAbs would consider that the simultaneous evolution of targeted and enzyme inhibitor therapies coupled with other therapies are in developing stages which will give them severe competition after some time. Their market share may get eroded by new NSCLC therapeutics which is likely to provide better pharmacological effect at competitive pricing.

Large clinical development pipeline for NSCLC therapeutics is expected to grow at tremendous rates in coming years. Pharmaceutical companies are investing significant amount of funds in clinical trials which may help large number of patients. But these therapeutics have prove their worth in clinical trials along with statistically significant data on safety and efficacy will be required. They will also take few years in passing regulatory hurdles and marketing authorization before providing medical care to NSCLC patients.

"Global Non Small Cell Lung Cancer Market & Pipeline Insight" Report Highlights:

  • NSCLC Therapy Market Overview
  • Mechanism of NSCLC Therapeutics
  • NSCLC Therapy Market Dynamics: Drivers, Challenges & Future Prospects)
  • NSCLC Drug Pipeline by Phase, Company & Country
  • NSCLC Clinical Pipeline: 268 Drugs
  • Majority of NSCLC Drugs in Phase-II Trials: 99
  • Marketed NSCLC Drugs: 30

Table of Contents

1. Introduction to Non Small Cell Lung Cancer

2. Mechanism of Non Small Cell Lung Cancer Therapeutics

3. Non Small Cell Lung Cancer Therapy Market Overview

  • 3.1 Market Scenario
  • 3.2 Non Small Cell Lung Cancer Pipeline Overview

4. Non Small Cell Lung Cancer Therapy Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Challenges

5. Non Small Cell Lung Cancer Therapy Market Future Prospects

6. Non Small Cell Lung Cancer Drug Pipeline by Phase, Company & Country

  • 6.1 Unknown
  • 6.2 Research
  • 6.3 Preclinical
  • 6.4 Clinical
  • 6.5 Phase-I
  • 6.6 Phase-I/II
  • 6.7 Phase-II
  • 6.8 Phase-II/III
  • 6.9 Phase-III
  • 6.10 Preregistration
  • 6.11 Registered

7. Marketed Non Small Cell Lung Cancer Drugs

8. Suspended & Discontinued Non Small Cell Lung Cancer Drug Pipeline

  • 8.1 No Development Reported
  • 8.2 Discontinued
  • 8.3 Suspended

9. Competitive Landscape

  • 9.1 AstraZeneca
  • 9.2 Biodesix
  • 9.3 Chugai Pharmaceutical
  • 9.4 Eli Lily
  • 9.5 GlaxoSmithKline
  • 9.6 Merck
  • 9.7 Novartis AG
  • 9.8 Pfizer
  • 9.9 Roche
  • 9.10 Transgene
  • Figure 1-1: Classification of Lung Cancer
  • Figure 1-2: Treatments Available for NSCLC
  • Figure 1-3: Categorization of NSCLC on The Basis of Stages
  • Figure 2-1: Steps Involved in NSCLC Metastasis
  • Figure 2-2: Mechanism of Tyrosine Kinase Inhibitors
  • Figure 2-3: Mechanism of Angiogenesis Inhibitors
  • Figure 2-4: Mode of Action of NSCLC Vaccines
  • Figure 3-1: Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
  • Figure 3-2: Non Small Cell Lung Cancer Pipeline by Phase (Number), 2015
  • Figure 3-3: No Development Reported in Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
  • Figure 3-4: No Development Reported in Non Small Cell Lung Cancer Pipeline by Phase (Number), 2015
  • Figure 3-5: Discontinued Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
  • Figure 3-6: Discontinued Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
  • Figure 3-7: Suspended Non Small Cell Lung Cancer Pipeline by Phase (%), 2015
  • Figure 3-8: Suspended Non Small Cell Lung Cancer Pipeline by Phase (Number), 2015
Back to Top